Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Sep;32(9):956-61.
doi: 10.1097/INF.0b013e3182947cf8.

Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants

Michael Cohen-Wolkowiez  1 , Mario Sampson, Barry T Bloom, Antonio Arrieta, James L Wynn, Karen Martz, Barrie Harper, Gregory L Kearns, Edmund V Capparelli, David Siegel, Daniel K Benjamin Jr, P Brian Smith; Best Pharmaceuticals for Children Act–Pediatric Trials Network
Collaborators, Affiliations
Clinical Trial

Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants

Michael Cohen-Wolkowiez et al. Pediatr Infect Dis J. 2013 Sep.

Abstract

Background: Limited pharmacokinetic (PK) data of metronidazole in premature infants have led to various dosing recommendations. Surrogate efficacy targets for metronidazole are ill-defined and therefore aimed to exceed minimum inhibitory concentration of organisms responsible for intra-abdominal infections.

Methods: We evaluated the PK of metronidazole using plasma and dried blood spot samples from infants ≤32 weeks gestational age in an open-label, PK, multicenter (N = 3) study using population PK modeling (NONMEM). Monte Carlo simulations (N = 1000 virtual subjects) were used to evaluate the surrogate efficacy target. Metabolic ratios of parent and metabolite were calculated.

Results: Twenty-four premature infants (111 plasma and 51 dried blood spot samples) were enrolled: median (range) gestational age at birth 25 (23-31) weeks, postnatal age 27 (1-82) days, postmenstrual age 31 (24-39) weeks and weight 740 (431-1466) g. Population clearance (L/h/kg) was 0.038 × (postmenstrual age/30) and volume of distribution (L/kg) of 0.93. PK parameter estimates and precision were similar between plasma and dried blood spot samples. Metabolic ratios correlated with clearance.

Conclusion: Simulations suggested the majority of infants in the neonatal intensive care unit (>80%) would meet the surrogate efficacy target using postmenstrual age-based dosing.

PubMed Disclaimer

References

    1. Uhari M, Seppanen J, Heikkinen E. Imipenem-cilastatin vs. tobramycin and metronidazole for appendicitis-related infections. Pediatr Infect Dis J. 1992;11:445–450. - PubMed
    1. Brook I. Bacteremia due to anaerobic bacteria in newborns. J Perinatol. 1990;10:351–356. - PubMed
    1. Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newborns: pathogenesis, prevention and management. Drugs. 2008;68:1227–1238. - PubMed
    1. Vohr BR, Wright LL, Dusick AM, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993–1994. Pediatrics. 2000;105:1216–1226. - PubMed
    1. Yeh TC, Chang JH, Kao HA, Hsu CH, Hung HY, Peng CC. Necrotizing enterocolitis in infants: clinical outcome and influence on growth and neurodevelopment. J Formos Med Assoc. 2004;103:761–766. - PubMed

Publication types